Zhejiang Huahai

The main products include high-density polyethylene bottles and polypropylene caps for pharmaceuticals.

Zhejiang Huahai Import & Export, a subsidiary of Zhejiang Huahai Pharmaceutical, builds a trading platform using Huahai’s resources and expertise.

Huahai Pharma partners with Taizhou Vocational and Technical College to establish a training program for pharmaceutical industry talent.

Huahai Pharmaceutical fosters an environment that encourages employees to perform at their best.

Huahai Pharma treats environmental protection as the foundation of its sustainability, guided by the principle of ‘Development in Harmony with Environment Protection.’

Huahai Pharmaceutical originates from the mission of “Care for Life & Serve the Society”, which motivates its people.

Huahai Pharmaceutical takes the health of the public as its mission. It devotes itself to providing high-quality medicinal and health products to global patients and to continuously improving the accessibility of its products, to improve the life quality of the people.

Founded in 1989 in Zhejiang, China, Zhejiang Huahai Pharmaceutical employs over 8,000 people and operates in chemical drugs, biologics, cell therapy, and trade across 40+ subsidiaries worldwide.

With the cause for human health as its duty, Huahai Pharmaceutical Co., Ltd. is devoted to provide global patients with high-quality medical health products, and continuously improve product accessibility for higher life standard of people.

Zhejiang Huahai Pharmaceutical Co., Ltd. owns and manages all website content, protected by global copyright laws.

The U.S. Food and Drug Administration (FDA) sends a warning letter to Zhejiang Huahai Pharmaceutical Co., Ltd. for compliance violations. The letter, dated June 6, 2025, highlights concerns under the MARCS-CMS inspection system. The agency cites issues related to regulatory adherence in pharmaceutical manufacturing or distribution, though specifics are not detailed in the notice.

Jun 2025U.S. Food and Drug AdministrationNews article

The FDA is disputing media reports questioning the quality of generic drugs amid a large recall of contaminated heart medications. The agency is defending its oversight role as scrutiny grows over potential safety risks in the generic pharmaceutical supply chain.

Feb 2019BioPharma DiveNews article

A Chinese pharmaceutical company receives $43 million in government funding amid operational or regulatory challenges. The financial aid aims to stabilize the firm’s production or research capabilities. Details on the company’s specific struggles or the funding’s allocation remain unspecified.

Oct 2018ETHealthworld.com | PharmaNews article

The FDA inspected a Chinese active pharmaceutical ingredient (API) manufacturer linked to the global valsartan recall after detecting a carcinogenic impurity in its valsartan supply. Regulators found significant compliance issues during the two-week plant inspection, prompting criticism of the company’s quality control practices. The impurity, identified as NDMA, has raised concerns about patient safety in multiple markets.

Sep 2018Fierce PharmaNews article